Please login to the form below

Deal Watch table for November 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during November 2014.

For an indepth analysis of these deals, read 'Pharma deals during November 2014'

Licensor acquired / licensee acquirer	Product / technology	Deal type	Headline ($m)
Allergan / Actavis	Dermatology / ophthalmology portfolio	Company acquisition	66,000
Omega Pharma / Perrigo	OTC portfolio	Company acquisition	4,500
Cystic Fibrosis Foundation /Royalty Pharma	Vertex's CF portfolio	Royalty stream acquisition	3,300
Indivior / Reckitt Benckiser	Pharma business unit	Business unit divestment	3,200
Almirall / AstraZeneca	Eklira and Duaklir	Business unit acquisition	3,075
Pfizer / Merck KGaA	PD-L1 and PD-1 CP inhibitors	Co-development and co-marketing alliance	2,850
UCB (Kremers Urban Pharma) /Advent International and Avista Capital Partners	Generics portfolio	Company divestment	1,530
Proteostasis Therapeutics / Astellas	Therapeutics modulating Unfolded Protein Response - multiple programmes	Discovery collaboration	1,200
Intacia / Servier	ICTA 650 (injection free GLP-1 agonist)	Licence	1,051
Geron Corporation / J&J (Janssen)	GRN163L, Imetelstat and tolerase inhibitor	Licence	935
Prosensa / BioMarin	Drisapersen – for Duchenne muscular dystrophy	Company acquisition	840
Galecto Biotech / BMS	TD139 galectin-3 inhibitor for Idiopathic pulmonary fibrosis	Option	444
AstraZeneca / Aegerion	Myalet (metreleptin) injection for leptin deficiency	Product acquisition	325
Transposagen Biopharmaceuticals/ J&J (Janssen)	Allogeneic Chimeric Antigen Receptor T-cells (CAR-T) therapies	Licence & research collaboration	292
Modern Biosciences / J&J (Janssen Biotech)	Bone protection compounds in RA	Research collaboration	275
Definiens / AstraZeneca (through MedImmune)	Tissue Phenomics Dx oncology biomarkers	Company acquisition	150
Knight Therapeutics / Gilead Sciences	Priority review voucher for Miltefosine	Acquisition of voucher	125
AVEO Oncology / Ophthotech Corporation	VEGF tyrosine kinase inhibitor tivozanib	Research and exclusive option to license	106
University of Michigan / PDL Biopharma	Cerdelga (eliglustat) sold by Vertex	Acquisition 75% royalty stream	66
Five Prime Therapeutics / BMS	FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor)	Research collaboration	30